ADRB2 and breast cancer: In the breast cancer study, the β2-AR–KO mice at the BALB/c background and the β-blocker propranolol demonstrated an increased intratumor frequency of CD8+ T cells with an effector phenotype and an increased efficacy of anti–PD-1 checkpoint blockade.